Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

76 Press Releases
DateTitleCompany
11 Aug 14 ASTELLAS PHARMA EMEA ANNOUNCES NEW SENIOR APPOINTMENTS Astellas Pharma EMEA
08 Aug 14 Cancer Research UK and Cancer Research Technology Join Forces with Astellas on Autophagy to Find New Cancer Treatments ASTELLAS PHARMA INC.,
Published by
PR Newswire
09 Jul 14 Astellas Submits U.S. New Drug Application for Isavuconazole for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis ASTELLAS PHARMA INC.,
Published by
PR Newswire
22 May 14 ASTELLAS ANNOUNCES GROUNDBREAKING €1.5m PROGRAMME TO TACKLE OBSTETRIC FISTULA IN KENYA Astellas Pharma Europe,
Published by
Forster comms
16 Apr 14 Astellas US Promotes Jeffrey Bloss to SVP of Medical Affairs for the Americas ASTELLAS PHARMA INC.,
Published by
PR Newswire
07 Apr 14 ASTELLAS ANNOUNCES MARKETING AUTHORISATION APPLICATION FOR XTANDI™ (ENZALUTAMIDE) FOR CHEMOTHERAPY-NAÏVE METASTATIC PROSTATE CANCER Astellas Pharma Inc
18 Mar 14 FIRST PATIENTS ENROLLED INTO EUROPEAN PHASE III PROGRAMME FOR POTENTIAL FIRST IN CLASS ORAL TREATMENT FOR ANAEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) Astellas Pharma Europe Ltd.
24 Sep 13 POST HOC ANALYSIS SUGGESTS THAT BETMIGA™ MAY RELIEVE OVERACTIVE BLADDER SYMPTOMS WHERE PRIOR ANTIMUSCARINIC TREATMENT HAS FAILED Astellas Pharma Europe Ltd.,
Published by
Astellas Pharma Europe Ltd
01 Aug 13 Astellas and FibroGen Announce the Initiation of a Phase 2 Clinical Study in Japan of ASP1517/FG-4592 for Treatment of Anemia of Chronic Kidney Disease Astellas,
Published by
Pharmiweb.com
11 Jul 13 New treatment for the management of advanced prostate cancer Astellas,
Published by
PharmiWeb.com
24 Jun 13 XTANDI™? (ENZALUTAMIDE) AUTHORISED IN THE EUROPEAN UNION (EU) FOR ADVANCED PROSTATE CANCER Astellas Pharma Europe Ltd
24 May 13 Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan Astellas Pharma Inc.,
Published by
Business Wire
23 May 13 ASTELLAS RECEIVES MARKETING AUTHORISATION FOR VESOMNITM FROM THE NETHERLANDS MEDICINES EVALUATION BOARD ASTELLAS PHARMA EUROPE B.V,
Published by
red door communications
26 Apr 13 POSITIVE CHMP OPINION FOR XTANDI™ (ENZALUTAMIDE) IN ADVANCED PROSTATE CANCER Astellas
21 Mar 13 Nagasaki University and Astellas Launch Collaborative Research for Screening New Anti-Dengue Virus Drugs for Neglected Tropical Diseases Astellas Pharma Inc.,
Published by
Business Wire
21 Mar 13 Tokyo Institute of Technology and Astellas Launch Collaborative Research for New Anti-Dengue Virus Drugs for Neglected Tropical Diseases Astellas Pharma Inc.,
Published by
Business Wire
14 Mar 13 European Commission approves new pre-treatment options for QUTENZAT (8% capsaicin patch) in peripheral neuropathic pain Astellas Pharma Europe Ltd.,
Published by
Pegasus
11 Mar 13 Non-inferiority Observed in Phase III Clinical Trial of Seasonal Flu Vaccine ASP7374 Astellas
22 Jan 13 Astellas' New Headquarters for the Americas Awarded LEED Gold Certification ASTELLAS PHARMA INC.,
Published by
PR Newswire
11 Dec 12 New phase II data demonstrates significant activity of quizartinib in relapsed or refractory acute myeloid leukaemia (AML) patients1,2 Astellas Pharma Inc.,
Published by
Business Wire
19 Oct 12 MIRABEGRON RECEIVES POSITIVE CHMP OPINION FOR TREATMENT OF OVERACTIVE BLADDER SYMPTOMS Astellas Pharma Ltd,
Published by
Red Door Communications
03 Oct 12 Astellas Pharma US Receives CEO Cancer Gold Standard Accreditation Astellas
01 Oct 12 Medivation and Astellas Announce New Data From XTANDI® (enzalutamide) Pivotal Study Astellas
01 Oct 12 AVEO and Astellas Announce New Data Presented at ESMO 2012 Congress Demonstrating the Safety and Tolerability Profile of Tivozanib in Patients with Advanced Kidney Cancer AVEO Oncology & Astellas Pharma Inc.,
Published by
Business Wire
30 Aug 12 Real-world efficacy of QUTENZA™ (8% capsaicin patch) confirms phase-III trial results, with improved patient quality of life and reduced use of healthcare resources Astellas Pharma Europe Ltd
14 Aug 12 Astellas Pharma Europe Ltd. appoints Dr Susan Wood as Senior Director, Market Access Astellas Pharma Europe Ltd
24 Jul 12 Astellas initiates head-to-head study comparing QUTENZA™ (8% capsaicin patch) and pregabalin in the treatment of peripheral neuropathic pain Astellas Pharma Europe Ltd
10 Jul 12 DIFICLIR™ (fidaxomicin), the first new antibiotic for Clostridium difficile infection since the 1950s, accepted for restricted use within Scotland Astellas
27 Jun 12 ASTELLAS ANNOUNCES SUBMISSION OF EUROPEAN MARKETING AUTHORISATION APPLICATION FOR ENZALUTAMIDE FOR THE TREATMENT OF MEN WITH ADVANCED PROSTATE CANCER POST-CHEMOTHERAPY Astellas Pharma Inc,
Published by
Red Health
27 Jun 12 Astellas Announces Submission of European Marketing Authorisation Application for Enzalutamide for the Treatment of Men with Advanced Prostate Cancer Post-Chemotherapy Astellas,
Published by
Business Wire
Advertising